{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:55:12Z","timestamp":1781524512296,"version":"3.54.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T00:00:00Z","timestamp":1553990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.biopha.2019.108838","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T07:16:44Z","timestamp":1554880604000},"page":"108838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Midazolam: Safety of use in palliative care"],"prefix":"10.1016","volume":"114","author":[{"given":"Iwona","family":"Zaporowska-Stachowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Tiffany","family":"Oduah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Stachowiak-Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"\u0141uczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Sopata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.108838_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable Cancer: a systematic review","volume":"34","author":"Teunissen","year":"2007","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2019.108838_bib0010","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11096-015-0094-3","article-title":"Medication use during end-of-life care in a palliative care centre","volume":"37","author":"Masman","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2019.108838_bib0015","series-title":"Drugs in Palliative Care","author":"Dickman","year":"2012"},{"key":"10.1016\/j.biopha.2019.108838_bib0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15360288.2017.1279502","article-title":"A review of agents for palliative sedation\/continuous deep sedation: pharmacology and practical applications","volume":"31","author":"Bodnar","year":"2017","journal-title":"J. Pain Palliat. Care Pharmacother."},{"issue":"August (4)","key":"10.1016\/j.biopha.2019.108838_bib0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/11209320-000000000-00000","article-title":"Oromucosal midazolam: a review of its use in pediatric patients with prolonged acute convulsive seizures","volume":"14","author":"Garnock-Jones","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.biopha.2019.108838_bib0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical reactions to benzodiazepines: literature review and treatment options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2019.108838_bib0035","article-title":"Sedacja w opiece paliatywnej","author":"\u0141uczak","year":"2018","journal-title":"Interna Szczeklika, Medycyna Praktyczna, Krak\u00f3w"},{"key":"10.1016\/j.biopha.2019.108838_bib0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpainsymman.2005.06.009","article-title":"Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced Cancer","volume":"31","author":"Navigante","year":"2006","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2019.108838_bib0045","article-title":"Adding midazolam to ketamine for procedural sedation reduces emergence reactions in adults","volume":"2011","author":"Richard","year":"2011","journal-title":"NEJM J. Watch."},{"key":"10.1016\/j.biopha.2019.108838_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.annemergmed.2010.09.010","article-title":"Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial","volume":"57","author":"Sener","year":"2011","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0885-3924(90)90020-K","article-title":"Subcutaneous midazolam infusion in palliative care","volume":"5","author":"Bottomley","year":"1990","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2019.108838_bib0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/026921639100500310","article-title":"Use of midazolam in palliative care","volume":"5","author":"McNamara","year":"1991","journal-title":"Palliat. Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0885-3924(96)00051-6","article-title":"Midazolam for intractable hiccup","volume":"12","author":"Wilcock","year":"1996","journal-title":"J. Pain Symptom Manage."},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.108838_bib0070","first-page":"62","article-title":"The use of midazolam and haloperidol in cancer patients at the end of life","volume":"53","author":"Radha Krishna","year":"2012","journal-title":"Singapore Med. J."},{"issue":"9","key":"10.1016\/j.biopha.2019.108838_bib0075","first-page":"951","article-title":"Seizures in palliative care Can Fam Physician","volume":"59","author":"Tradounsky","year":"2013","journal-title":"Sep"},{"issue":"1","key":"10.1016\/j.biopha.2019.108838_bib0080","first-page":"58","article-title":"Stany nagl\u0105ce w zaawansowanej fazie choroby nowotworowej","volume":"80","author":"Kluziak","year":"2011","journal-title":"Nowiny Lekarskie"},{"issue":"March\u2013April (2)","key":"10.1016\/j.biopha.2019.108838_bib0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/104990910302000214","article-title":"Management of hiccups in the palliative care population","volume":"20","author":"Smith","year":"2003","journal-title":"Am. J. Hosp. Palliat. Care"},{"issue":"1","key":"10.1016\/j.biopha.2019.108838_bib0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/jpm.2012.0205","article-title":"i wsp. OPCARE9.Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion","volume":"16","author":"Lindqvist","year":"2013","journal-title":"J. Palliat. Med."},{"issue":"3\u20134","key":"10.1016\/j.biopha.2019.108838_bib0095","first-page":"105","article-title":"Leki niezb\u0119dne w opiece paliatywnej 2013","volume":"7","author":"Lichodziejewska-Niemierko","year":"2013","journal-title":"Medycyna Paliatywna w Praktyce"},{"key":"10.1016\/j.biopha.2019.108838_bib0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000542-198210000-00005","article-title":"Comparative evaluation of intravenous agents for rapid sequence induction\u2014thiopental, ketamine, and midazolam","volume":"57","author":"White","year":"1982","journal-title":"Anesthesiology 10"},{"issue":"4","key":"10.1016\/j.biopha.2019.108838_bib0105","first-page":"241","article-title":"Post\u0119powanie lekarza rodzinnego wobec chorych na raka w ostatnich dniach \u017cycia","volume":"2","author":"Buczkowski","year":"2003","journal-title":"Polska Medycyna Paliatywna"},{"issue":"1","key":"10.1016\/j.biopha.2019.108838_bib0110","first-page":"19","article-title":"Management of dyspnoea in cancer patients","volume":"3","author":"Leppert","year":"2011","journal-title":"Medycyna Paliatywna\/Palliative Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0115","first-page":"2624","article-title":"Post\u0119powanie w wybranych objawach chorobowych","author":"Krajnik","year":"2018","journal-title":"Interna Szczeklika, Medycyna Praktyczna, Krak\u00f3w"},{"issue":"1","key":"10.1016\/j.biopha.2019.108838_bib0120","first-page":"3","article-title":"OPIEKA PALIATYWNA\/ HOSPICYJNA \/ MEDYCYNA PALIATYWNA","volume":"80","author":"\u0141uczak","year":"2011","journal-title":"Nowiny Lekarskie"},{"issue":"May\u2013June (3)","key":"10.1016\/j.biopha.2019.108838_bib0125","first-page":"121","article-title":"Midazolam as an anti-emetic","volume":"10","author":"Rodol\u00e0","year":"2006","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"195-197","key":"10.1016\/j.biopha.2019.108838_bib0130","first-page":"209","article-title":"Praktyczny przewodnik po diagnostyce i terapii chor\u00f3b nowotworowych. Szpital Kliniczny Przemienienia Pa\u0144skiego Uniwersytetu Medycznego im","volume":"160-161","author":"Batura-Gabryel","year":"2017","journal-title":"Karola Marcinkowskiego w Poznaniu, Pozna\u0144"},{"key":"10.1016\/j.biopha.2019.108838_bib0135","series-title":"Drugs in Palliative Care","author":"Dickman","year":"2012"},{"issue":"March (3)","key":"10.1016\/j.biopha.2019.108838_bib0140","first-page":"221","article-title":"Midazolam for long-term treatment of intractable hiccup","volume":"29","author":"Moro","year":"2005","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2019.108838_bib0145","series-title":"Recommended Methods for The Detection and Assay of Barbiturates and Benzodiazepines in Biological Specimens. Manual for Use by National Laboratories","author":"United Nations","year":"1997"},{"key":"10.1016\/j.biopha.2019.108838_bib0150","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1111\/j.1365-2125.1983.tb02272.x","article-title":"Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites","volume":"16","author":"Ziegler","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0155","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/0300-9572(88)90002-0","article-title":"Clinical pharmacology of Dormicum (midazolam) and Anexate (flumazenil)","volume":"16","author":"Amrein","year":"1988","journal-title":"Resuscitation"},{"key":"10.1016\/j.biopha.2019.108838_bib0160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1191\/0269216304pm1006oa","article-title":"Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review","volume":"19","author":"Fonzo-Christe","year":"2005","journal-title":"Palliat. Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0165","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Christopher Gorski","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)09155-2","article-title":"Bimodal distribution of renal cytochrome P450 3A activity in humans","volume":"50","author":"Haehner","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199835010-00003","article-title":"Clinical pharmacology of midazolam in infants and children","volume":"35","author":"Blumer","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.108838_bib0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.1875-9114.1985.tb03411.x","article-title":"Midazolam: the first water-soluble benzodiazepine; pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia","volume":"5","author":"Kanto","year":"1985","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/clpt.1982.133","article-title":"Physiologie and temporal variation in hepatic elimination of midazolam","volume":"32","author":"Klotz","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00562804","article-title":"The pharmacokinetics of midazolam in man","volume":"19","author":"Smith","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0195","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/clpt.1981.217","article-title":"Midazolam kinetics","volume":"30","author":"Allonen","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0200","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1111\/j.1365-2125.1983.tb02270.x","article-title":"Pharmacokinetics and bioavailability of midazolam in man","volume":"16","author":"Heizmann","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","article-title":"Effect of age, gender, and obesity on midazolam kinetics","volume":"61","author":"Greenblatt","year":"1984","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopha.2019.108838_bib0210","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/bja\/57.9.866","article-title":"Age and nature of operation influence the pharmacokinetics of midazolam","volume":"57","author":"Harper","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.biopha.2019.108838_bib0215","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1111\/j.1365-2125.1983.tb02269.x","article-title":"Safety aspects of midazolam","volume":"16","author":"Schlappi","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2019.108838_bib0220","first-page":"69","article-title":"Guidelines for the clinical us of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal","volume":"6","author":"Nelson","year":"1999","journal-title":"Can. J. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/CMPed.S8330","article-title":"Nasal and buccal treatment of midazolam in epileptic seizures in pediatrics","volume":"6","author":"Ulgey","year":"2012","journal-title":"Clin. Med. Insights Pediatr."},{"key":"10.1016\/j.biopha.2019.108838_bib0230","series-title":"Care Beyond Cure. Management of Pain and Other Symptoms","first-page":"115p","author":"Plant","year":"2009"},{"key":"10.1016\/j.biopha.2019.108838_bib0235","series-title":"Benzodiazepines. in: Pharmacokinetics of Anaesthesia","author":"Prys-Roberts","year":"1984"},{"key":"10.1016\/j.biopha.2019.108838_bib0240","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00679782","article-title":"The pharmacokinetics of midazolam in paediatric patients","volume":"37","author":"Payne","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0245","first-page":"2211","article-title":"Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration\/2nd comm.: Pharmacokinetical aspects (author\u2019s transl)","volume":"31","author":"Crevoisier","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.biopha.2019.108838_bib0250","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2125.2002.01665.x","article-title":"Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers","volume":"54","author":"Pecking","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0255","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.1988.tb03330.x","article-title":"Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration","volume":"25","author":"Clausen","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0260","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2125.1998.00781.x","article-title":"Midazolam pharmacokinetics following intravenous and buccal administration","volume":"46","author":"Schwagmeier","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0265","first-page":"963","article-title":"Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans","volume":"56","author":"Gudmundsdottir","year":"2001","journal-title":"Pharmazie"},{"key":"10.1016\/j.biopha.2019.108838_bib0270","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/bja\/79.5.575","article-title":"Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients","volume":"79","author":"Bj\u00f6rkman","year":"1997","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.biopha.2019.108838_bib0275","first-page":"89","article-title":"Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential","volume":"64","author":"Fukuta","year":"1997","journal-title":"ASDC J. Dent. Child."},{"key":"10.1016\/j.biopha.2019.108838_bib0280","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1552-4604.1997.tb04358.x","article-title":"Pharmacokinetics and Pharmacodynamics of Midazolam After Intranasal Administration","volume":"37","author":"Burstein","year":"1997","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2019.108838_bib0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.1988.tb03330.x","article-title":"Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration","volume":"25","author":"Clausen","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0290","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1111\/j.1365-2125.1983.tb02270.x","article-title":"Pharmacokinetics And Bioavailability Of Midazolam in Man","volume":"16","author":"Heizmann","year":"1983","journal-title":"Br. J. Clin. Pharmac"},{"key":"10.1016\/j.biopha.2019.108838_bib0295","series-title":"Intravenous Anesthetics. xPharm: The Comprehensive Pharmacology Reference","first-page":"1","author":"Capey","year":"2007"},{"key":"10.1016\/j.biopha.2019.108838_bib0300","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Theraputics","first-page":"159","author":"Goodman","year":"2011"},{"key":"10.1016\/j.biopha.2019.108838_bib0305","series-title":"Palliative Care Formulary","author":"Twycross","year":"2008"},{"key":"10.1016\/j.biopha.2019.108838_bib0310","series-title":"Oxford Textbook of Palliative Care for Children","author":"Goldman","year":"2006"},{"issue":"5","key":"10.1016\/j.biopha.2019.108838_bib0315","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \"pie\"","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108838_bib0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans*","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0325","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40262-014-0166-x","article-title":"Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers","volume":"53","author":"Brill","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.108838_bib0330","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1007\/s11095-015-1752-9","article-title":"The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery","volume":"32","author":"Brill","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2019.108838_bib0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0970-9185.76639","article-title":"A comparison of equisedative infusions of propofol and midazolam for conscious sedation during spinal anesthesia - a prospective randomized study","volume":"27","author":"Patki","year":"2011","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0340","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/dmd.112.045567","article-title":"Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients","volume":"41","author":"Bjelland","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108838_bib0345","first-page":"69","volume":"63","author":"Katzung","year":"2018"},{"key":"10.1016\/j.biopha.2019.108838_bib0350","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0009-9236(99)90084-X","article-title":"The effect of age on the pharmacokinetics and pharmacodynamics of midazolam","volume":"65","author":"Albrecht","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0355","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2044.1996.tb07785.x","article-title":"What changes drug metabolism in critically ill patients-III? Effect of pre-existing disease on the metabolism of midazolam","volume":"51","author":"Park","year":"1996","journal-title":"Anaesthesia."},{"key":"10.1016\/j.biopha.2019.108838_bib0360","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/bja\/60.7.762","article-title":"Pharmacokinetics of midazolam in anasthetized cirrhotic patients","volume":"60","author":"Trouvin","year":"1988","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.biopha.2019.108838_bib0365","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.me.29.020178.001225","article-title":"The Disposition and Effects of Sedatives and Analgesics in Liver Disease","volume":"29","author":"Hoyumpa","year":"1978","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0370","first-page":"1616","article-title":"Drug administration in hepatic disease, N. Engl","volume":"309","author":"Williams","year":"1983","journal-title":"J. Med."},{"key":"10.1016\/j.biopha.2019.108838_bib0375","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0380","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/gut.27.2.190","article-title":"Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis","volume":"27","author":"MacGilchrist","year":"1986","journal-title":"Gut."},{"key":"10.1016\/j.biopha.2019.108838_bib0385","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00000542-198311000-00005","article-title":"The pharmacokinetics of midazolam in chronic renal failure patients","volume":"59","author":"Vinik","year":"1983","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopha.2019.108838_bib0390","first-page":"149","article-title":"The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients","volume":"42","author":"Driessen","year":"1991","journal-title":"Acta Anaesthesiol. Belg."},{"key":"10.1016\/j.biopha.2019.108838_bib0395","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam., J. Am","volume":"20","author":"Nolin","year":"2009","journal-title":"Soc. Nephrol."},{"issue":"October","key":"10.1016\/j.biopha.2019.108838_bib0400","article-title":"Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults","volume":"10","author":"Simon","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2019.108838_bib0405","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF03261971","article-title":"Drug interactions in dying patients","volume":"35","author":"Frechen","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2019.108838_bib0410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40264-013-0066-2","article-title":"Should midazolam drug\u2013drug interactions be of concern to palliative care physicians?","volume":"36","author":"Kotlinska-Lemieszek","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2019.108838_bib0415","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction."},{"issue":"October (5)","key":"10.1016\/j.biopha.2019.108838_bib0420","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007691-199910000-00003","article-title":"Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans","volume":"21","author":"Nakajima","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2019.108838_bib0425","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin","volume":"37","author":"Backman","year":"1996","journal-title":"Epilepsia."},{"key":"10.1016\/j.biopha.2019.108838_bib0430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2125.2007.02970.x","article-title":"Interaction between midazolam and clarithromycin in the elderly","volume":"65","author":"Quinney","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0435","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108838_bib0440","doi-asserted-by":"crossref","first-page":"84S","DOI":"10.1002\/j.1875-9114.1995.tb02909.x","article-title":"Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal","volume":"15","author":"Riesenman","year":"1995","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0445","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/clpt.2011.178","article-title":"Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam","volume":"91","author":"Yang","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0450","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0455","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"Saari","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0460","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"December (6)","key":"10.1016\/j.biopha.2019.108838_bib0465","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol: an update","volume":"37","author":"Kudo","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.108838_bib0470","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2019.108838_bib0475","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting","volume":"14","author":"English","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"issue":"6","key":"10.1016\/j.biopha.2019.108838_bib0480","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/bja\/82.6.900","article-title":"Fentanyl inhibits metabolism of midazolam: competitive inhibition of cyp3a4 in vitro","volume":"82","author":"Oda","year":"1999","journal-title":"Br. J. Anaesth."},{"issue":"March (3)","key":"10.1016\/j.biopha.2019.108838_bib0485","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1128\/AAC.01242-10","article-title":"Kari Laine. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4","volume":"55","author":"Gr\u00f6nlund","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2019.108838_bib0490","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/1389200215666141125121511","article-title":"Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450","volume":"15","author":"Niwa","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2019.108838_bib0495","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108838_bib0500","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3928\/0048-5713-19950301-09","article-title":"Toxicity and adverse consequences of benzodiazepine use","volume":"25","author":"Ashton","year":"1995","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.biopha.2019.108838_bib0505","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1100\/tsw.2006.243","article-title":"Anterograde and retrograde effects of benzodiazepines on memory","volume":"6","author":"Beracochea","year":"2006","journal-title":"ScientificWorldJournal."},{"key":"10.1016\/j.biopha.2019.108838_bib0510","article-title":"Addiction: Part I. Benzodiazepines-side effects, abuse risk and alternatives","author":"Longo","year":"2000","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.biopha.2019.108838_bib0515","series-title":"Anesthesia and Analgesia in Laboratory Animals","author":"Meyer","year":"2008"},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.108838_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198814010-00001","article-title":"Pharmacokinetics and clinical use of flumazenil (Ro 15-1788)","volume":"14","author":"Klotz","year":"1988","journal-title":"Clin. Pharmacokinet."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219305955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219305955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:26:11Z","timestamp":1781522771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219305955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":104,"alternative-id":["S0753332219305955"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108838","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midazolam: Safety of use in palliative care","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"108838"}}